36 results
8-K
BLPH
Bellerophon Therapeutics, Inc.
4 Mar 24
Departure of Directors or Certain Officers
5:25pm
with respect to Proposal 1 and Proposal 2, and no other voting rights except as required by law or as set forth in the Certificate of Designation.
The Series
8-K
EX-10.1
BLPH
Bellerophon Therapeutics, Inc.
30 Jan 24
Entry into a Material Definitive Agreement
9:29am
”). Subscriber hereby acknowledges and agrees to the entire terms of the Certificate of Designation, including, without limitation, the voting rights
8-K
BLPH
Bellerophon Therapeutics, Inc.
30 Jan 24
Entry into a Material Definitive Agreement
9:29am
Stock otherwise has no voting rights except as otherwise required by the General Corporation Law of the State of Delaware.
The Series A Preferred Stock
DEFA14A
BLPH
Bellerophon Therapeutics, Inc.
3 Jan 24
Additional proxy soliciting materials
1:49pm
, postponed, or delayed, to allow stockholders additional time to exercise their voting rights by submitting their voting instructions. The Special
8-K
EX-10.1
BLPH
Bellerophon Therapeutics, Inc.
9 Jun 23
Departure of Directors or Certain Officers
4:05pm
be deferred, on a mandatory basis or at the election of the Participant in a manner that complies with Section 409A of the Code.
(2) Voting Rights … . A Participant shall have no voting rights with respect to any Restricted Share Units.
(3) Dividend Equivalents. The Award agreement for Restricted
424B5
qsyaeo h3w5frw
31 May 23
Prospectus supplement for primary offering
4:40pm
424B5
3rwaetf
17 Jul 20
Prospectus supplement for primary offering
5:01pm
424B5
dwp0c3mxog0x5ddd0p
20 May 20
Prospectus supplement for primary offering
4:03pm
424B5
h28ga27al3rzf8gm
20 May 20
Prospectus supplement for primary offering
4:02pm
424B5
f42wlww
18 May 20
Prospectus supplement for primary offering
4:02pm
424B5
kt5q4b b8
31 Mar 20
Prospectus supplement for primary offering
7:03am